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A retrospective nationwide study on the use of intravenous
(IV) zanamivir in patients receiving intensive care who were
pretreated with oseltamivir in the Netherlands was performed.
In 6 of 13 patients with a sustained reduction of the viral load,
the median time to start IV zanamivir was 9 days (range, 4–11
days) compared with 14 days (range, 6–21 days) in 7 patients
without viral load reduction (P 5 .052). Viral load response
did not inﬂuence mortality. We conclude that IV zanamivir as
late add-on therapy has limited effectiveness. The effect of an
immediate start with IV zanamivir monotherapy or in com-
bination with other drugs need to be evaluated.
During last year’s inﬂuenza pandemic, life-threatening disease
was encountered in a proportion of patients [1–4]. Despite ex-
tensive treatment, the mortality rate among these patients re-
mained high [2]. One of the problems encountered was the
development of resistance to oseltamivir. In addition, in isolated
cases, oseltamivir use was complicated due to absent gastric
mobility [5]. Currently, zanamivir is the alternative drug of
choice to use when oseltamivir-resistant viruses develop. How-
ever, at this moment it is only approved for use as an inhaled
formulation. Respiratory problems following inhalation, dys-
function of ventilators due to blockade of the ﬁlters by the
lactose carrier, and suboptimal drug disposition are issues as-
sociated with its formulation [6, 7]. The use of intravenous (IV)
zanamivir may be an option to overcome these problems.
Currently, only limited peer-reviewed data in humans and one
study in primates have been published [8–12]. We here report
a retrospective observational nationwide study in the Nether-
lands on the antiviral efﬁcacy of IV zanamivir.
METHODS
Patients included in this study were identiﬁed, retrospectively,
through a request to all registered medical microbiologists in the
Netherlands. A standardized form was provided to collect rele-
vant clinical and virological data. All patient data were reported
anonymously. The decision to start IV zanamivir and the du-
ration of therapy were not standardized and depended on the
clinical judgment of the treating physician. Initially, compas-
sionate use was granted by GlaxoSmithKline; from January 2010
onward, this was continued by the National Institute for Public
Health and the Environment. Intravenous zanamivir was pro-
vided for patients unable to use oseltamivir or in whom treat-
ment with IV zanamivir was considered desirable for other
reasons. Nasopharyngeal swabs, nose washes (upper respiratory
tract [URT] samples), tracheal aspirates, and broncheo-alveolar
lavages (lower respiratory tract [LRT] samples) were collected
during routine care.
Inclusion criteria for patients in this study were as follows:
laboratory-conﬁrmed pandemic inﬂuenza A (H1N1) infection
by real-time reverse-transcription polymerase chain reaction
(RT-PCR); admission to an intensive care unit (ICU) in a Dutch
hospital; use of IV zanamivir for .48 hours; and availability of
follow-up virological samples. Patients with proven resistance to
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BRIEF REPORT d JID 2011:204 (1 September) d 777zanamivir at baseline or at ICU admittance were excluded from
the study.
Detection and quantiﬁcation of viral RNA and screening for
the neuraminidase (NA) H275Y oseltamivir resistance mutation
was performedin all centers bymeans of standardized RT-PCR–
based methods. To obtain sequences of NA genes, viral RNA
was reverse transcribed and subsequently ampliﬁed using gene-
speciﬁc primers (sequences are available upon request). Attempts
to culture virus were made at sample viral loads of .43 10
3virus
particles (vp) per milliliter. Phenotypic sensitivity to oseltamivir
and zanamivir was measured using the NA-star neuraminidase
inhibitor resistance detection kit (Applied Biosystems, Nieu-
werkerk aan den IJsel, the Netherlands). See the supplementary
data for more technical details.
Clinical data were extracted from the medical records.
Immunosuppression was deﬁned as any of the following: re-
ceipt of treatment for any cancer within 6 months before in-
ﬂuenza infection, the use of any immunosuppressive
medication to prevent transplant rejection or for management
of pulmonary or autoimmune conditions, or a diagnosis of
AIDS. Acquired respiratory distress syndrome (ARDS) was
deﬁned as bilateral inﬁltrates on chest radiographs, with a Pa
O2/F IO2 ratio of ,200 mm Hg in the absence of cardiogenic
pulmonary edema.
The viral response to treatment with IV zanamivir was de-
termined by the differences in viral load between a sample col-
lected closest to the day of the start of IV zanamivir (baseline
sample) and those obtained at follow-up. Sustained reduction
of the viral load was deﬁned as a decrease of $1l o g 10 vp/mL for
at least 10 days. In case of death or cessation of IV zanamivir
treatment, the last sample collected while the patient was still
receiving therapy was considered for the endpoint of analysis. If
the reduction of the viral load took .7 days of treatment to
occur, it was considered not to be treatment related. For sta-
tistical analysis between groups, the Mann–Whitney U test was
used. P values of ,.05 were considered to be signiﬁcant.
The study protocol was reviewed and approved by the med-
ical ethics board of the Erasmus University Medical Center
(study no. 2010-162). Informed consent was waived because
patient inclusion was performed retrospectively and anony-
mously. There was no sponsor involvement in the design, data
collection, and analysis of this study.
RESULTS
Based on data provided by GlaxoSmithKline during the in-
ﬂuenza season in the Netherlands, 26 ICU patients were treated
with IV zanamivir. Overall, we obtained clinical data of 19 pa-
tients from 6 hospitals. Of these 19 patients, 6 did not meet the
inclusion criteria. Reasons for exclusion from the study were
death (n 5 2), recovery and treatment interruption within 48
hours after start of IV zanamivir (n 5 2), absence of samples for
virological evaluation (n 5 1), and proven resistance to zana-
mivir before admittance to the ICU (n 5 1).
The patient characteristics are summarized in Table 1.M o s t
patients had a pre-existing medical condition and were im-
munocompromised. All patients were pretreated with oral osel-
tamivir for a median period of 5 days (range, 1–18 days).
Oseltamivir was dosed at 75 mg every 12 hours or its pediatric
equivalent,exceptin3patients(patients4,5,and8)inwhom150
mg every 12 hours wasused.Three patients receivedIV zanamivir
monotherapy (patients 7, 9, and 13), whereas the remaining 10
patients received IV zanamivir combined with continued use
of oseltamivir. No other antiviral therapy was prescribed.
The median baseline viral load was 3 3 10
4 vp/mL, (range,
,17–1.2 3 10
8 vp/mL) in the URT samples and 2.3 3 10
5 vp/mL
(range,,17–9.83 10
6vp/mL)intheLRTsamples.Twopatients
(patients 1 and 12) had an undetectable viral load in the
URT sample but a high viral load in the LRT sample at baseline.
One patient (patient 5) had an undetectable viral load in the
LRT sample but a high viral load in the URT sample at baseline.
The response analysis was complicated for 2 patients because
their baseline samples were obtained 3 days before IV zanamivir
initiation (patients 8 and 10). Overall, sustained reduction of the
viral load was observed in only 6 patients (Figure 1). Three pa-
tients had persistent undetectable viral loads after 7 days of
treatment (patients 7, 9, and 13). There were no signiﬁcant dif-
ferences between baseline viral loads in the URT and LRT sam-
ples of patients with and without viral load reduction (P 5 .315
and P 5 .250,respectively).Overall,themedianintervalbetween
ﬁrst onset of symptoms and start of IV zanamivir was 11 days
(range, 4–21 days). However, among patients who had a sus-
tained reduction of the viral load, the median time to start of IV
zanamivir was 9 days (range, 4–11 days), compared with 14 days
(range, 6–21 days) among patients in whom treatment had no
effect (P 5 .05). All 3 patients receiving monotherapy with IV
zanamivir showed a sustained viral load response.
A sequence could be obtained from viruses isolated from
10 patients before start of IV zanamivir, but sequences could not
be obtained from viruses isolated from patients 7, 9, and 12.
Viruses isolated from patients 3, 6, 7, and 13 carried the H275Y
oseltamivir resistance mutation in NA as determined by se-
quencing and/or RT-PCR speciﬁc for the H275Y mutation. No
other mutations associated with drug resistance were found in
the NA genes. For 9 patients, phenotypic resistance data could
bemeasuredinisolatesobtainedbeforestartofIVzanamivir. All
9 isolates were susceptible to zanamivir (Table 1).Virus could
not be cultured from all 19 samples eligible for culture that were
obtained after the start of IV zanamivir, despite relatively high
loads with a median of 4.0 3 10
5 vp/mL (range, 4.9 3 10
3–14 3
10
5 vp/mL).
Twelve patients were admitted to the ICU because of re-
spiratory failure; 1 patient was already admitted. All patients
needed supplemental oxygen: 12 patients were mechanically
778 d JID 2011:204 (1 September) d BRIEF REPORTTable 1. Selected Patient Characteristics and Outcomes of 13 Patients Receiving IV Zanamivir
Viral resistance to Oseltamivir Baseline viral load, vp/mL
Patient no. Underlying disease
Age in
years Immunocompromised ARDS
Oseltamivir
pretreatment,
days
Amino acid
position 275
in the viral NA
(N1 numbering) IC50, nmol/L
URT
sample
LRT
sample
Time to
start of
Zanamivir,
days
Zanamivir
IC50, nmol/L
1 log10
decrease in
viral load Outcome
1 None 46 No Yes 4 H 0.4 (S) ND 4.9 3 10
3 12 0.1 (S) No Survived
2 Cerebral vasculitis,
pulmonary embolisms
long-term high-dosage
prednisone use
41 Yes Yes 14 H NR 1.0 3 10
5 . 14 NR No Died
3 Chronic myeloid leukemia,
bone marrow transplantation,
graft-vs-host disease, clinical
signiﬁcant aortic valve stenosis
58 Yes Yes 18
a H 132.8 (R) 4.0 3 10
4 3.76 3 10
5 19 0.2 (S) No Died
4 None 14 No Yes 1 H 0.2 (S) 2.0 3 10
5 9.8 3 10
6 4 0.2 (S) Yes Died
5 Down syndrome, acute
lymphoblastic leukemia
5 Yes Yes 5 H 0.4 (S) 1.0 3 10
4 ND 14 0.1 (S) No Survived
6 Follicular lymphoma 59 Yes Yes 7 H/Y
b 7.1 (R)
b 1.2 3 10
8 . 11 0.4 (S) Yes Died
7 Minimal change nephropathy,
prednisone use
39 Yes Yes 7 Y NR . 9.0 3 10
3 9 NR Yes Survived
8 Obesity 42 No Yes 4 H 0.4 (S) 4.3 3 10
4 6.5 3 10
5 6 0.1 (S) No Survived
9 Obesity, ovarian adenoma
(identiﬁed during
hospital admission)
30 No Yes 6 NR NR 4.5 3 10
2 . 9 NR Yes Survived
10 Systemic lupus erythematosis 40 Yes Yes 3 H 0.3 (S) . 3.5 3 10
6 10 0.2 (S) Yes Died
11 Acute myeloid leukemia 49 Yes Yes 6 H 0.3 (S) 3 3 10
4 . 10 0.3 (S) No Died
12 Alcohol abuse 52 No Yes 1 NR NR ND 9.1 3 10
5 21 NR No Survived
13 Biliary atresia, hepatocellular
carcinoma, liver transplantation
1 Yes No 9 Y NR 3.0 3 10
4 . 11 0.2 (S) Yes Survived
NOTE. Reference median inhibitory concentration (IC50) values (n 5 60) for oseltamivir are 0.20 6 0.08 nmol/L (median 1/2 95% CI) and for zanamivir are 0.22 6 0.12 nmol/L. ARDS, acquired respiratory distress
syndrome; H, histidine; IC50, median inhibitory concentration; LRT, lower respiratory tract; NA, neuraminidase; ND, not detectable; NR, no result could be obtained; R, resistant; S, susceptible; URT, upper respiratory tract;
vp, virus particles; Y, tyrosine.
a Plus inhaled zanamivir therapy for 9 days.
b Virus mixture of wild type and mutants with an H275Y mutation.
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9ventilated and 4 patients required additional extracorporeal
membrane oxygenation support. In all mechanically ventilated
patients, ARDS was diagnosed. The overall mortality was
signiﬁcant, with a total number of 6 deaths. There was no re-
lation between viral response and survival, with death occurring
in3of6patientsinthe groupwithsustainedviralloadreduction
Figure 1. Virological response to intravenous (IV) zanamivir in 13 patients. A, Change in baseline viral load detected in the upper respiratory tract (URT);
B, change in baseline viral load detected in the lower respiratory tract (LRT). Eight patients were treated for .10 days, and 5 patients were treated for
,10 days. Of those 5 patients, 2 died and 3 clinically recovered, and zanamivir IV medication was stopped (patients 7, 9, and 13). Because patient 12 had
undetectable viral loads in the URTsample, these data are not included in the figure for change in baseline URT viral load. Each line represents a single
patient. Data obtained from patients with a sustained viral load reduction are depicted in green, and data for those without a viral response are depicted
in red; the black dashed line represents the delta viral load of 21 log10 virus particles (vp) per milliliter.
780 d JID 2011:204 (1 September) d BRIEF REPORTandin3of7patientsinthenonrespondergroup.Mostdeaths(5
of6)occurredinpatientswithanimpairedimmune system.The
remaining 7 surviving patients were discharged after a median
hospital stay of 52 days (range, 11–62 days), of which 37 days
(range, 39–77 days) were spent in the ICU. All patients received
broad-spectrum antibiotics at least once. In none of the patients
was IV zanamivir stopped because of serious adverse events.
DISCUSSION
In this study, which is to our knowledge the largest published
peer-reviewed case series to date, we have retrospectively ana-
lyzed the virological response to IV zanamivir treatment in pa-
tients pretreated with oral oseltamivir for severe inﬂuenza
infection.Aconsistentvirologicalresponsetoadd-onIVtherapy
was seen in only 6 of 13 patients. There was a trend toward an
increased likelihood of response for those who started IV za-
namivir at an earlier stage of disease.
This study has several limitations. Due to the retrospective
nature, the absence of a control group, and the limited number
of patients enrolled, we cannot make a deﬁnitive conclusion on
the clinical efﬁcacy of IV zanamivir. Still, we feel that our ob-
servations are important, because they are not in line with
previously published reports on individual patients with en-
couraging results [8–10]. Several factors may explain the limited
effectiveness of IV zanamivir seen in 7 of 13 patients. First, the
patients included were severely ill as reﬂected by the high
number of immunocompromised patients, poor response to
oral oseltamivir, and extended duration of hospitalization. A
potential explanation for the limited virological efﬁcacy may
have been the development of viruses resistant to zanamivir
[13]. Unfortunately, because we were unable to obtain viral
isolates or relevant viral sequences after start of zanamivir
therapy, it remains unknown to what extent resistance con-
tributed to the absence of virological response. Another expla-
nation for the absence of response could be that insufﬁcient
zanamivir levels were achieved at some sites of active viral rep-
lication. Further detailed pharmacological studies are warranted
to investigate this possibility. Of interest is a recent ﬁnding in
patients with inﬂuenza A (H3N2) infection that the combina-
tion of oseltamivir and zanamivir may be associated with a de-
creased inhibition of viral replication. However, in that study all
patients did clear the virus rapidly [14]. In this light, it is im-
portant to note that all patients described in our study had been
pretreated with oseltamivir monotherapy. Resistance to oselta-
mivir was found in only 4 of them. Therefore, we hypothesize
that the same mechanism accounts for the limited efﬁcacy of
both IV zanamivir and oral oseltamivir.
Because of the prolonged viral replication before the start of
IV zanamivir, irreversible lung injury may already have oc-
curred. Thus, the relatively late start with IV zanamivir in the
course of disease may have compromised its potential efﬁcacy.
This is suggested by the shorter intervals between illness onset
and initiation of IV zanamivir in patients with a sustained
suppression of the viral load. The extensive damage to the lungs
may have resulted in viral salvage sites inaccessible to the im-
mune system and antiviral medication. Earlier start of IV za-
namivir may help to prevent formation of these sites. Indeed,
previously published data show that early start with neur-
aminidase inhibitors results in a better outcome in hospitalized
patients [15]. Finally, it is well recognized that bacterial super-
infections may also contribute to clinical deterioration; we
cannot rule out the possibility that this has also occurred in our
population, despite the fact that all of our patients received
antibiotic therapy.
In conclusion, the use IV zanamivir as late add-on therapy
for H1N1 virus–infected patients in the ICU showed limited
antiviral effectiveness. In our selected population, reduction
of viral load did not affect mortality. Further studies evalu-
ating earlier start with IV zanamivir monotherapy therapy
alone or in combination with other treatment strategies are
needed.
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Supplementary Data are available at The Journal of Infectious Diseases online.
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